FDA Approves CSL Behring's Kcentra
4/30/2013 9:04:08 AM
More...
|
CSL Behring Receives European Health Authorities' Approval of Berinert® for Short-Term Prophylaxis in Adults and Children
4/16/2013 10:49:11 AM
More...
|
CSL Behring Donates Medicine Used in Treating Bleeding Disorders to World Federation of Hemophilia
4/4/2013 10:51:06 AM
More...
|
CSL Behring Receives FDA Approval to Expand the Indication for Corifact®
2/28/2013 8:31:18 AM
More...
|
CSL Behring Announces New Vial Size of Privigen® for Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura
2/22/2013 8:38:05 AM
More...
|
CSL Behring's Grassroots Advocacy Grants Promote Early Diagnosis and Access to Care for Patients With Rare Diseases
1/30/2013 9:43:26 AM
More...
|
CSL Behring Enrolls First Patient in Global Pediatric Phase III Pivotal Study off Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (Rix-FP) to Treat Hemophilia B
1/22/2013 9:17:44 AM
More...
|
CSL Behring Release: New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
1/22/2013 9:12:21 AM
More...
|
CSL Behring and Its Employees Give Back to Their Communities by Supporting a Range of Charities Year-Round
1/4/2013 9:49:05 AM
More...
|
CSL Behring Launches Its First Co-Pay Assistance Program to Ease Financial Burden of Treating Hereditary Angioedema
1/2/2013 9:51:06 AM
More...
|
|